Probitas Partners Global Growth Continues With the Announcement of New Managing Directors
Probitas Partners is excited to announce the promotion of four new managing directors who will continue to drive the firm’s growth. These promotions are in recognition of contributions to the success of the firm and in anticipation of continued success on behalf of our fund sponsor and institutional investor clients.
Additionally, Probitas is excited to expand its real estate advisory capabilities to include providing bespoke access to large scale U.S. commercial real estate opportunities to a targeted universe of the most active and sophisticated investors globally.
Probitas Partners was founded in 2001 and is a leading independent global placement advisory firm. The firm continues to be led by the longest-standing senior management team of any global placement advisor. The founders of Probitas congratulate their colleagues on their promotions and look forward to the next decade of great partnerships.
Caryn Feinberg has been promoted to Managing Director on the project management team. She is primarily responsible for leading origination efforts in the U.S. Prior to joining Probitas Partners, Caryn worked for SecondMarket, Inc. and before that, was Director of Investor Relations for Global Infrastructure Partners, a private equity infrastructure fund. Caryn previously also worked for Citigroup in New York.
Haakon Gresvig has been promoted to Managing Director on the relationship management (Distribution) team. He is primarily responsible for maintaining key investor relationships in Europe and the Middle East as well as acting as head of Probitas’ European office. Prior to joining Probitas Partners, Haakon was a Director at Wedge Alternatives, a boutique placement agent in London focused on raising capital for private equity and hedge funds. Prior to that, Haakon worked at Goldman Sachs in New York and London.
Ray Tsao has been promoted to Managing Director on the project management team. He is primarily responsible for leading fund due diligence and execution of alternative asset fund placement processes. Ray started with Probitas in 2009 and has been associated with and led many of our successful fundraises. Prior to joining Probitas Partners, Ray served as an investment banking associate in the Technology Group at Credit Suisse in San Francisco.
John Caley joins Probitas Partners as a Managing Director – Direct Real Estate. John brings 27 years of industry experience in identifying large-scale assets with unique investment attributes (off-market, broker-controlled pocket listings, direct ownership, sensitive timing, etc.) that create bespoke and often time-sensitive direct investment opportunities. Prior to joining Probitas Partners, John was a Senior Managing Director at Grubb & Ellis’ Investment Management Platform and has held senior executive positions with Gemini Rosemont, Rexford Industrial, Transwestern and PM Realty Group.
“We are pleased to acknowledge the growing strength and capabilities of our team. This has resulted in our promotion of these individuals. It is very gratifying for the three founding partners of Probitas Partners to be able to attract and retain such a high-quality team that will continue to build on our 17-year track record of success,” said Craig Marmer, a founding partner.
In addition, “Recognizing the clear market trend for large institutional investors to seek direct commercial real estate exposure, we are excited to expand our global real estate advisory business to include discrete access to very large-scale commercial real estate investment opportunities across the U.S.,” said Michael Hoffmann, a founding partner.
About Probitas Partners
Rewarding Partnerships Since 2001
For 17 years Probitas Partners has identified and affiliated with the highest quality established and emerging alternative investment fund managers from around the world, advising on over 90 fundraises and franchise developments and representing over $68 billion of capital commitments for private equity, real estate, infrastructure, real assets and credit funds. As part of the firm’s commitment to excellence and in support of our clients’ investment goals, we continue to deliver the market’s leading independent research offering, providing institutional investors with gratis access to our propriety data, surveys, white papers and tailored landscapes by geography, sector and strategy.
Michael Hoffmann, 415-402-0700
Co-Founder & Managing Director
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu